Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Schlumberger NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Schlumberger NV trades at $48.07 (market cap $71.40B). The key difference: Schlumberger NV is the larger of the two by market cap, and Schlumberger NV pays a 2.47% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SLB | |
|---|---|---|
Market Cap | $39.89B | $71.40B |
Sector | Health | Energy |
52-Week High | $491.22 | $58.01 |
52-Week Low | $278.09 | $31.72 |
Enterprise Value | $38.15B | $79.62B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SLB trades at $47.76, up 1.1% with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of $0.52, beating expectations, and maintains strong cash flow from operations at $6.49B. Recent news highlights a seven-year Kuwait contract expansion and digital marketplace launch, supporting growth prospects amid oil price fluctuations.
Outlook: Analyst consensus is bullish with an $62.14 price target (30% upside). Risks include oil price sensitivity and Middle East exposure, but digital transformation and contract wins provide stability. Valuation metrics (P/E 21.04, P/S 1.95) appear reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
